Humoral and cellular immune response to severe acute respiratory syndrome coronavirus‐2 vaccination in hemodialysis and kidney transplant patients
Nephrology — Swai J, Gui M, Long M, et al. | September 14, 2021
Researchers herein described trends of immune response-proportions among end-stage renal disease patients on renal replacement therapy in the Coronavirus disease-2019 vaccination programs.
From six online-databases, researchers identified 27 eligible studies describing humoral and cellular immune response proportions for up to 4 weeks post booster-vaccination.
These studies involved 2,789 end-stage renal disease patients.
Lower proportions of humoral and cellular immune responses were recorded among hemodialysis and kidney transplant patients relative to healthy controls.
However, by the fourth week, there appeared an improvement in hemodialysis patients' response proportions, reaching near healthy-control levels.
Improvement also occurred in kidney transplant patients' lower responses' proportions but these remained significantly lower than healthy controls throughout 4-weeks.
For kidney transplant patients, it might be inadequate to implement the "one-size-fits-all" vaccination scheme.
Read the full article on Nephrology